68.10
price up icon2.79%   1.85
after-market After Hours: 68.10
loading
Arcellx Inc stock is traded at $68.10, with a volume of 595.32K. It is up +2.79% in the last 24 hours and up +28.98% over the past month. Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$66.25
Open:
$67.28
24h Volume:
595.32K
Relative Volume:
0.78
Market Cap:
$3.42B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-22.78
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+9.73%
1M Performance:
+28.98%
6M Performance:
-19.46%
1Y Performance:
+32.65%
1-Day Range:
Value
$66.44
$68.84
1-Week Range:
Value
$61.00
$68.84
52-Week Range:
Value
$47.86
$107.37

Arcellx Inc Stock (ACLX) Company Profile

Name
Name
Arcellx Inc
Name
Phone
240-327-0603
Name
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Name
Employee
163
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ACLX's Discussions on Twitter

Compare ACLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACLX
Arcellx Inc
68.10 3.42B 76.81M -162.42M -122.49M -2.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-03-24 Initiated Cantor Fitzgerald Overweight
May-31-24 Initiated Piper Sandler Overweight
Mar-07-24 Initiated Morgan Stanley Overweight
Jan-04-24 Reiterated Needham Buy
Dec-19-23 Initiated Scotiabank Sector Outperform
Oct-30-23 Initiated TD Cowen Outperform
Oct-17-23 Initiated UBS Buy
May-18-23 Initiated Truist Buy
Apr-14-23 Initiated Robert W. Baird Outperform
Mar-14-23 Initiated Stifel Buy
Feb-13-23 Initiated H.C. Wainwright Buy
Dec-13-22 Resumed BofA Securities Buy
Oct-31-22 Initiated Guggenheim Buy
Oct-27-22 Initiated Needham Buy
Jul-20-22 Initiated Canaccord Genuity Buy
Mar-01-22 Initiated BofA Securities Buy
Mar-01-22 Initiated SVB Leerink Outperform
View All

Arcellx Inc Stock (ACLX) Latest News

pulisher
04:16 AM

Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

04:16 AM
pulisher
01:51 AM

Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World

01:51 AM
pulisher
Jun 05, 2025

Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media

Jun 05, 2025
pulisher
Jun 05, 2025

Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jun 03, 2025
pulisher
May 31, 2025

How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com

May 31, 2025
pulisher
May 29, 2025

Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

May 29, 2025
pulisher
May 28, 2025

Arcellx Inc Holds Annual Stockholders Meeting - TipRanks

May 28, 2025
pulisher
May 23, 2025

New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga

May 23, 2025
pulisher
May 22, 2025

Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister

May 22, 2025
pulisher
May 21, 2025

Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire

May 21, 2025
pulisher
May 21, 2025

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph

May 21, 2025
pulisher
May 21, 2025

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga

May 21, 2025
pulisher
May 20, 2025

Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

May 19, 2025
pulisher
May 16, 2025

Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

May 16, 2025
pulisher
May 16, 2025

Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks

May 15, 2025
pulisher
May 15, 2025

Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World

May 15, 2025
pulisher
May 14, 2025

Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st

May 14, 2025
pulisher
May 14, 2025

Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks

May 14, 2025
pulisher
May 14, 2025

Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks

May 14, 2025
pulisher
May 14, 2025

Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks

May 14, 2025
pulisher
May 14, 2025

Arcellx Announces Positive Phase 2 Study Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace

May 14, 2025
pulisher
May 14, 2025

Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks

May 14, 2025
pulisher
May 14, 2025

Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com

May 14, 2025
pulisher
May 12, 2025

Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks

May 12, 2025
pulisher
May 12, 2025

Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey

May 12, 2025
pulisher
May 12, 2025

Arcellx, Inc. (NASDAQ:ACLX) Receives $109.31 Average Target Price from Brokerages - Defense World

May 12, 2025
pulisher
May 11, 2025

Scotiabank Has Lowered Expectations for Arcellx (NASDAQ:ACLX) Stock Price - Defense World

May 11, 2025
pulisher
May 10, 2025

Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail

May 10, 2025
pulisher
May 10, 2025

Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail

May 10, 2025
pulisher
May 10, 2025

Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Needham Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail

May 10, 2025
pulisher
May 10, 2025

Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks

May 10, 2025
pulisher
May 09, 2025

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 09, 2025
pulisher
May 09, 2025

Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks

May 09, 2025
pulisher
May 09, 2025

Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks

May 08, 2025
pulisher
May 08, 2025

Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks

May 08, 2025
pulisher
May 08, 2025

Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks

May 08, 2025
pulisher
May 08, 2025

ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire

May 08, 2025

Arcellx Inc Stock (ACLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Cap:     |  Volume (24h):